Effects of topical antiglaucoma medications on the ocular surface

Penny Asbell, Natalia Potapova

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.

Original languageEnglish (US)
Pages (from-to)27-40
Number of pages14
JournalOcular Surface
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Ophthalmic Solutions
Filtering Surgery
Keratitis
Hyperemia
Metaplasia
Patient Compliance
Tears
Glaucoma
Multicenter Studies
Cell Biology
Therapeutics
Epithelial Cells
Biopsy

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Effects of topical antiglaucoma medications on the ocular surface. / Asbell, Penny; Potapova, Natalia.

In: Ocular Surface, Vol. 3, No. 1, 01.01.2005, p. 27-40.

Research output: Contribution to journalArticle

Asbell, Penny ; Potapova, Natalia. / Effects of topical antiglaucoma medications on the ocular surface. In: Ocular Surface. 2005 ; Vol. 3, No. 1. pp. 27-40.
@article{fb701dc67ae747b883321cd45058bbcc,
title = "Effects of topical antiglaucoma medications on the ocular surface",
abstract = "The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.",
author = "Penny Asbell and Natalia Potapova",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/S1542-0124(12)70120-9",
language = "English (US)",
volume = "3",
pages = "27--40",
journal = "Ocular Surface",
issn = "1542-0124",
publisher = "Ethis Communications, Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of topical antiglaucoma medications on the ocular surface

AU - Asbell, Penny

AU - Potapova, Natalia

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.

AB - The side effects of topical antiglaucoma medications and their preservatives range from ocular discomfort to sight-threatening alterations of the ocular surface. Conjunctival hyperemia, decreased tear production and function, and superficial punctate keratitis are among the most common signs seen on routine clinical examination. Squamous cell metaplasia and changes in cell morphology have been demonstrated by impression cytology studies and evaluation of biopsy specimens, and inflammatory effects are documented by the presence of inflammatory markers. The adverse effects of topical antiglaucoma eyedrops interfere with the treatment of glaucoma on two levels: first, the discomfort produced by the eye drops discourages patient compliance; and, second, long-term treatment with eyedrops is associated with a higher failure of filtration surgery. The detailed mechanism of inflammatory response and/or direct toxicity of eye drops has yet to be determined, but it may vary with the different classes of eye drops, different preservatives, and durations of treatments. Upcoming multicenter trials for new antiglaucoma eye drops should specifically evaluate ocular surface effects.

UR - http://www.scopus.com/inward/record.url?scp=14844288059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844288059&partnerID=8YFLogxK

U2 - 10.1016/S1542-0124(12)70120-9

DO - 10.1016/S1542-0124(12)70120-9

M3 - Article

VL - 3

SP - 27

EP - 40

JO - Ocular Surface

JF - Ocular Surface

SN - 1542-0124

IS - 1

ER -